This article is more than 5 years old. Information may no longer be current.

AHA issues grant to develop therapies for Duchenne muscular dystrophy

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Bijan K . Dey, PhD, a scientist at The RNA Institute at the University at Albany, received a grant from the American Heart Association to support his research on Duchenne muscular dystrophy and the associated cardiomyopathy.

HF is most common cause of death in people with Duchenne muscular dystrophy (DMD), a genetic degenerative disease that affects male children.

“DMD afflicts 1 in 3,000 live male births, representing over 2.5 million young boys between the ages of 2 and 7 worldwide,” Dey said in a press release from the University at Albany. “The goal of my research is to gain a better understanding of the pathophysiology of DMD and DMD-associated cardiomyopathy in molecular detail, and to devise a cutting edge platform for effective therapy.”

According to the release, patients with DMD-associated cardiomyopathy have an enlarged left ventricle and weakened cardiac wall muscles, are often restricted to wheelchairs starting in the first decade of life, and commonly die young of HF.

The grant will fund Dey’s research through 2020.